160 results about "Local injection" patented technology

A local renal delivery system includes a flow isolation assembly and a local injection assembly. The flow isolation assembly in one mode is adapted to isolate only a partial flow region along the outer circumference along the aorta wall such that fluids inject there are maintained to flow substantially into the renal arteries. Various types of flow isolation assemblies and local injection assemblies are described.

A renal flow system injects a volume of fluid agent into a location within an abdominal aorta in a manner that flows bilaterally into each of two renal arteries via their respectively spaced ostia along the abdominal aorta wall. A local injection assembly (100) includes two injection members (104, 106), each having an injection port (112) that couples to a source of fluid agent externally of the patient. The injection ports may be positioned within an outer region of blood flow along the abdominal aorta wall perfusing the two renal arteries.

A renal flow system injects a volume of fluid agent into a location within an abdominal aorta in a manner that flows bi-laterally into each of two renal arteries via their respectively spaced ostia along the abdominal aorta wall. A local injection assembly includes two injection members, each having an injection port that couples to a source of fluid agent externally of the patient. The injection ports may be positioned with an outer region of blood flow along the abdominal aorta wall perfusing the two renal arteries. A flow isolation assembly may isolate flow of the injected agent within the outer region and into the renals. The injection members are delivered to the location in a first radially collapsed condition, and bifurcate across the aorta to inject into the spaced renal ostia. A delivery catheter for upstream interventions is used as a chassis to deliver a bilateral local renal injection assembly to the location within the abdominal aorta.

The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and method to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders, local injections of oxysterols or cells (206) and implants (202) having agents or cells (203) to facilitate bone repair.

A method, using high intensity ultrasound, which may also be combined with a chemotherapy agent, that can result the direct destruction of tumor cells and in the reduction or elimination of local reoccurrence of cancer after removal of cancerous tissue, such as a surgical breast lumpectomy or surgical excision of a brain tumor. The method comprises either (1) the treatment of the tumor directly with High Intensity Focused Ultrasound, or (2) the treatment of the margins of the tissue surrounding the surgical cavity or void with ablative continuous wave high intensity ultrasound and a combination of a locally delivered chemotherapy agent and high intensity ultrasound, termed sonoporation. The present invention permits both the direct destruction (ablation) of tumor tissue as well as the destruction of tissue around the surgical margin and may include the enhanced local cellular uptake of locally injected chemotherapeutic drugs, all of which can be accomplished by a therapeutic ultrasound device used during surgery.

Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred IOP-lowering agents are angiostatic steroids, particularly anecortave acetate, and the most preferred route of administration is an anterior juxtascleral injection or implant. The invention is based in part on the discovery that anterior juxtascleral injections of anecortave acetate are capable of controlling intraocular pressure for sustained periods of from one to several months or more. This result is believed to be attributable to facilitation of access of the anecortave acetate to the trabecular meshwork via the anterior juxtascleral route of administration. This route of administration is also believed to be advantageous for other types of IOP-lowering agents, particularly molecules that cannot readily penetrate the cornea due to size or other physical properties.

The invention relates to hyaluronic acid which contains giant molecule hydrogel and is applied to injection or turbid liquor of salt thereof and a preparation method thereof; the turbid liquor of the invention is characterized in that hyaluronic acid or isosmotic solution of salt thereof serves as a carrier; water-insoluble macromolecular compound aqueous gel particle fully swelling in isosmotic solution is added. In the invention, the preparation of the turbid liquor has the steps as follows: preparing cross linking macromolecule compound or polymer particle so as to facilitate the compound or polymer particle to fully swelling in the isosmotic solution to form gel particles, then being mixed with hyaluronic acid or salting liquid dissolved in the isosmotic solution. The hyaluronic acid containing giant molecule hydrogel or the turbid liquor of salt thereof are applied to preparing injection for beauty care or medical treatment, which has the characteristics of easy injection, long-term local effect, good plasticity and fine biocompatibility; in local injection part, the invention is used as an isolating and lubricating pad which enables surrounding tissues to be fully repaired; the characteristic is even more pronounced in treating arthritis by bone joint cavity injection.

The invention provides a branched transport polymer characterized as having at least 10 amino acids and a ratio of histidine to non-histidine amino acids greater than 1.5, said branched transport polymer comprising one or more backbones, one or more terminal branches, and optionally, one or more non-terminal branches. The branched transport polymer may be associated with a pharmaceutical agent to form a pharmaceutical agent delivery composition useful for in vivo therapies based on local injection.

The invention provides an octreotide acetate freeze-dried combination for injection, which comprises octreotide acetate, mannitol and a proper amount of buffer substances, wherein the mass ratio of the octreotide acetate to the mannitol is 1:(450-500); and the buffer substances are lactic acid and sodium bicarbonate and can be tartaric acid and sodium tartrate. The invention also provides a preparation method of the composition. The composition provided by the invention is produced by adopting an aseptic technique; by striving to make the technological breakthrough in optimal pH range and optimal preparation temperature in a liquid medicine preparation process, the product stability is improved; and finally, a freeze-dried product is prepared. By adopting a quick-freezing mode for pre-freezing, a finished product has low related substance content and good re-solubility, can be preserved at room temperature for two months and can be refrigerated for two years, thereby facilitating the product transportation and delivery. By clinically matching with a solution, the combination has good stability and low local injection irritation. The invention provides a safe and effective octreotide acetate freeze-dried combination for injection, which has good and controllable quality, for clinics.

The invention provides a temperature-sensitive amphiphilic cyclodextrin polymer PCEC (polycaprolactone-polyethylene glycol-polycaprolactone, PCL-PEG-PCL). The polymer provided by the invention is the amphiphilic cyclodextrin polymer which is obtained by linking a PCL-PEG-PCL molecule with beta-CD (cyclodextrin) through utilizing the temperature-sensitive characteristic of a PCL-PEG-PCL triblock copolymer and the inclusion effect of beta-CD on a hydrophobic medicament, can effectively load and slowly release a hydrophobic or water-soluble medicament on the basis of the traditional hydrogel encapsulated water-soluble medicament, has proper critical gel temperature and can form in situ temperature-sensitive hydrogel after injection. According to the invention, the hydrophobic zone of the polymer is obviously enlarged, thereby effectively improving the loading capacity of the hydrogel on the hydrophobic medicament and obtaining high medicament encapsulation rate and medicament loading amount; and simultaneously, the controlled-release effect of the medicament after local injection delivery is realized by utilizing the temperature-sensitive gel performance of the polymer. The polymer provided by the invention has the following chemical structure shown in the specification.

A multi-level lithography processes for the fabrication of suspended structures are presented. The process is based on the differential exposure and developing conditions of several a plurality of resist layers, without harsher processes, such as etching of sacrificial layers or the use of hardmasks. These manufacturing processes are readily suited for use with systems that are chemically and/or mechanically sensitive, such as graphene. Graphene p-n-p junctions with suspended top gates formed through these processes exhibit high mobility and control of local doping density and type. This fabrication technique may be further extended to fabricate other types of suspended structures, such as local current carrying wires for inducing local magnetic fields, a point contact for local injection of current, and moving parts in microelectromechanical devices.

Devices, kits and methods for reducing the risk of infection at an injection or incision site are described herein. The device contains a bioadhesive, biocompatible and bioerodable material and one or more disinfectant agents. In the preferred embodiment, the material is formed of one ore more hydrogels Optionally, the device also contains one or more anesthetics to decrease discomfort. The device may be marked or calibrated to facilitate localized injection or incision at a pre-specified site on the skin or mucus membrane. After identifying or selecting the injection or incision site, the device is placed on the site for a time sufficient to achieve localized disinfection, and optionally localized anesthesia. Then the needle or surgical instrument is inserted through the composition into the site. Thereafter, the drug is administered, fluid is removed, in the case of an injection, or the surgical instrument is placed at the site, in the case of an incision. Then the needle or surgical instrument is removed from the site, and the device forms a continuous seal over the site. The disinfectant and/or anesthetic is delivered before, during, and/or after the treatment. Optionally, the disinfectant and/or anesthetic is released in a controlled-release manner. Optionally, the disinfectant and/or anesthetic may de delivered following a time-delay. In a second embodiment, the device may be placed at a site following the injection or incision at the site to reduce the risk of infection, provide anesthesia, and/or prevent reflux of blood or fluid following the injection or incision.

The invention relates to a drug composition for treating local inflammation, which uses methylprednisolone palmitate as an active composition. The drug composition consists of the methylprednisolone palmitate as the active composition and an inactive composition suitable for local injection, and is used for treating local inflammation of people or mammal through local injection.

The invention provides a stem cell injection for treating osteoarthritis cartilage defect and preparation and application thereof. The injection comprises fifth-generation umbilical cord mesenchymal stem cells and a liquid solvent, wherein the fifth generation umbilical cord mesenchymal stem cells are suspended in the liquid solvent, and the concentration is (2.0-3.0)x10<7> cells/ 4.5-5.0ml of the liquid solvent. The liquid solvent is normal saline, or autologous platelet-rich plasma, or a mixed solution of normal saline and human albumin, or a mixed solution of normal saline and autologous platelet-rich plasma. The human albumin accounts for 5-8% in volume by percentage. The normal saline accounts for 10% or below in volume by percentage. The injection is administered by intravenous injection or bone joint cavity local injection or the combination of the two, the cell injection amount of the intravenous injection is (1.0-1.5)x10<8> cells/ one time, and the cell injection amount of the bone joint cavity injection is (2.0-3.0)x10<7> cells/ one time/ one knee. The effect of the stem cell injection for treating the integrity degree of osteoarthritis cartilage is obviously superior to that of a traditional hyaluronic acid (HA) method.

The invention relates to a microsphere-containing gel for injection. The gel comprises a carrier and degradable polyester microspheres dispersed in the carrier and used for carrying out filling and supporting functions, wherein the carrier is prepared from high polymer material particles and a physiological buffer solution. The invention also relates to a preparation method of the microsphere-containing gel for injection. The method comprises the following steps: S1, preparing the carrier by using the high polymer material particles and the physiological buffer solution; and S2, uniformly dispersing the degradable polyester microspheres in the carrier to form the microsphere-containing gel for injection. The microsphere-containing gel for injection provides a short-term filling and supporting function through the high polymer material particles, and provides a long-term filling and supporting function through the degradable polyester microspheres. In addition, the degradable polyestermicrospheres are uniformly dispersed in the carrier, so that the problems of uneven filling caused by local injection can be solved.